Phase 3 Cardiovascular Clinical Trials
54 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 54 trials
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Atherosclerotic Cardiovascular Disease
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Cardiovascular Disease
Amgen11,000 enrolled243 locationsNCT07136012
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Phase 2Phase 3
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
MenopauseMenopause Related ConditionsCardiovascular+1 more
University of Colorado, Denver200 enrolled1 locationNCT06975111
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled751 locationsNCT07157774
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Cardiovascular Disease
AstraZeneca15,100 enrolled1264 locationsNCT07000357
Recruiting
Phase 3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Cardiovascular Disease
Amgen406 enrolled40 locationsNCT07293260
Recruiting
Phase 3
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)
Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring200 enrolled19 locationsNCT07094087
Recruiting
Phase 3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
Phase 3
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular RiskAcute Myocardial Infarction (AMI)
Novo Nordisk A/S10,000 enrolled970 locationsNCT06118281
Recruiting
Phase 3
Pelacarsen Roll-over Extension Program
Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals599 enrolled97 locationsNCT06875973
Recruiting
Phase 2Phase 3
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
ObesityCardiovascular DiseasesHypertension+3 more
University of Alabama at Birmingham160 enrolled1 locationNCT04971720
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled72 locationsNCT07517263
Recruiting
Phase 3
Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy
Myocardial Infarction (MI)Cardiovascular EventsPost Polypectomy Bleeding in Antiplatelet Patients
Chinese University of Hong Kong2,514 enrolled1 locationNCT07052799
Recruiting
Phase 3
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
Cardiovascular DiseasesDiabete Type 2
Montreal Heart Institute10,000 enrolled39 locationsNCT05633810
Recruiting
Phase 3
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
Atherosclerotic Cardiovascular Disease (ASCVD)Atherothrombotic Diseases
Hospital do Coracao7,713 enrolled13 locationsNCT06930885
Recruiting
Phase 3
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
Cardiovascular DiseasesDepression
VA Office of Research and Development132 enrolled1 locationNCT04877197